When to start cholesterol-lowering therapy in patients with coronary heart disease. A statement for healthcare professionals from the American Heart Association Task Force on Risk Reduction.
Grundy S, Balady G, Criqui M, Fletcher G, Greenland P, Hiratzka L, Houston-Miller N, Kris-Etherton P, Krumholz H, LaRosa J, Ockene I, Pearson T, Reed J, Smith S, Washington R. When to start cholesterol-lowering therapy in patients with coronary heart disease. A statement for healthcare professionals from the American Heart Association Task Force on Risk Reduction. Circulation 1997, 95: 1683-5. PMID: 9118557, DOI: 10.1161/01.cir.95.6.1683.Peer-Reviewed Original ResearchConceptsCholesterol-lowering therapyAggressive cholesterol-lowering therapyAtherosclerotic diseaseCholesterol loweringAmerican Heart Association Task ForceCholesterol-lowering trialsClinical atherosclerotic diseaseFuture coronary eventsHigh-risk patientsSubstantial clinical benefitMajority of patientsCoronary heart diseaseLDL cholesterol loweringPrimary care physiciansBenefits of therapyRisk-reducing treatmentsNonpharmaceutical approachesRecurrent CHDCoronary eventsCare physiciansClinical benefitCholesterol managementClinical managementHeart diseaseCholesterol reduction